N/A N=26 Tandem VR: Synchronized Nature-Based Experiences in Virtual Reality for Hospice Patients and Their Caregivers
Hospice · End of Life · Palliative Care
Primary: Quality of Life Domains — 1.68; 1.27 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=9 Phase 2 Clinical Trial of Crizotinib for Children and Adults With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas
Neurofibromatosis 2 · Progressive Vestibular Schwannoma (VS)
Primary: Volumetric Response Rate — 0; 9 Participants
N/A N=13 Analytical Treatment Interruption (ATI) to Assess the Immune System's Ability to Control HIV in Participants Who Became HIV-infected During the HVTN 703/HPTN 081 AMP Study
HIV Infection
Primary: Time to Meeting Criteria for ART Re-initiation — 17.1; 10.1; 13.3 Weeks
N/A N=50 3-year Follow-up of Patients Treated With Jetstream Combined With Ranger for Calcified Femoropopliteal Lesions
Peripheral Artery Disease
Primary: Freedom From Target Lesion Revascularization (TLR) — 100.0; 100.0; 98.4; 95.1 Percentage of lesions
Phase 4 N=13 A Post-authorization Study to Describe the Safety and Efficacy of Emapalumab for the Treatment of pHLH in Treatment Experienced Chinese Patients
Primary Hemophagocytic Lymphohistiocytosis
Primary: Permanent Discontinuation of Study Drug Due to Emapalumab-related Adverse Event — 0 Participants
N/A N=100 Interrupted Subdermal Suture Spacing During Linear Wound Closures and the Effect on Wound Cosmesis
Interrupted Subdermal Suture
Primary: Patient and Observer Scar Assessment Scale - Reviewer 1 — 13.14; 12.40; 2.46; 2.23 score on a scale — p=<0.05
N/A N=125 STAAR Visian Toric ICL Post-Approval Study
Myopic Astigmatism
Primary: Change in Axis Orientation of the TICL — 104; 4 Eyes
Phase 2 N=60 Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria (Cohort B2)
Uncomplicated Plasmodium Falciparum Malaria
Primary: Polymerase Chain Reaction (PCR) Corrected Adequate Clinical and Parasitological Response (ACPR) — 96.43; 96.67 Percentage of participants
Phase 2 N=21 Twice Weekly Steroids and Exercise as Therapy for DMD
Duchenne Muscular Dystrophy (DMD)
Primary: Change in BMI — 0.67; 1.34; 1.8 kg/m^2
N/A N=10 Acupuncture for Nasal Congestion in Allergic Rhinitis
Allergic Rhinitis
Primary: Change in Visual Analog Scale (VAS) From Baseline to 6 Weeks (6-week Value Compared to Baseline Value) — -8; -2 Scale points
Phase 2 N=59 Long-term Safety With Vedolizumab Intravenous (IV) in Pediatric Participants With Ulcerative Colitis (UC) or Crohn's Disease (CD)
Ulcerative Colitis · Crohn's Disease
Primary: Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) — 100; 83.3; 100; 100 percentage of participants
N/A N=28 Resiliency Programming for Caregivers of Children With Learning and Attentional Difficulties
Parenting · Stress · Learning Disabilities, Child
Primary: Feasibility of Study Enrollment — 28 Participants
Phase 1 N=62 Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor
Advanced Solid Tumor
Primary: Number of Participants Experienced Dose Limit Toxicities (DLT) — 0; 0 Participants
N/A N=32 Evaluating the Feasibility of VR for Pediatric Renal Biopsies
Pain, Procedural · Procedural Anxiety · Sedation Complication
Primary: Number of Participants Who "Strongly Agreed" They Would Recommend VR to Others Undergoing Similar Procedures — 0; 32 participants (patients)
Phase 2 N=136 Study Evaluating the Efficacy and Safety of Povorcitinib in Adults With Chronic Spontaneous Urticaria
Urticaria · Chronic Spontaneous Urticaria · Chronic Idiopathic Urticaria
Primary: Change From Baseline in the Urticaria Activity Score Over 7 Days (UAS7) at Week 12 — -17.90; -17.25; -19.83; -23.91 scores on a scale — p=0.8298